Use of an Ultrarapid Acting Insulin Analog with Control-IQ: A Case Report

Diabetes Technol Ther. 2022 Nov;24(11):856-857. doi: 10.1089/dia.2022.0192. Epub 2022 Oct 17.

Authors

Melissa J Schoelwer¹, Mark D DeBoer¹, Marc D Breton², Boris P Kovatchev²

Affiliations

¹ Department of Pediatrics, University of Virginia, Charlottesville, Virginia, USA.
² Center for Diabetes Technology, University of Virginia, Charlottesville, Virginia, USA.

No abstract available

Publication types

Case Reports
Letter
Research Support, N.I.H., Extramural

MeSH terms

Humans
Hypoglycemic Agents*
Insulin*

Substances

Insulin
Hypoglycemic Agents

Grants and funding

R01 DK129553/DK/NIDDK NIH HHS/United States